[go: up one dir, main page]

NO20054630L - Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser - Google Patents

Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser

Info

Publication number
NO20054630L
NO20054630L NO20054630A NO20054630A NO20054630L NO 20054630 L NO20054630 L NO 20054630L NO 20054630 A NO20054630 A NO 20054630A NO 20054630 A NO20054630 A NO 20054630A NO 20054630 L NO20054630 L NO 20054630L
Authority
NO
Norway
Prior art keywords
agonists
antagonists
applications
related reagents
methods
Prior art date
Application number
NO20054630A
Other languages
English (en)
Other versions
NO20054630D0 (no
Inventor
Martin Oft
Terrill K Mccianahan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20054630D0 publication Critical patent/NO20054630D0/no
Publication of NO20054630L publication Critical patent/NO20054630L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Tilveiebrakt bhr fremgangsmåter for behandling av tumorer. Spesielt blir fremgangsmåter tilveiebrakt for å modulere aktivitet av et cytokinmolekyl og dets reseptor.
NO20054630A 2003-03-10 2005-10-07 Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser NO20054630L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45367203P 2003-03-10 2003-03-10
PCT/US2004/007198 WO2004081190A2 (en) 2003-03-10 2004-03-09 Uses of il-23 agonists and antagonists; related reagents

Publications (2)

Publication Number Publication Date
NO20054630D0 NO20054630D0 (no) 2005-10-07
NO20054630L true NO20054630L (no) 2005-10-07

Family

ID=32990805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054630A NO20054630L (no) 2003-03-10 2005-10-07 Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser

Country Status (22)

Country Link
US (4) US7282204B2 (no)
EP (2) EP2108658B1 (no)
JP (4) JP4605798B2 (no)
CN (1) CN1759123B (no)
AT (1) ATE440864T1 (no)
AU (2) AU2004219625B9 (no)
BR (1) BRPI0408247A (no)
CA (1) CA2518262C (no)
CL (1) CL2004000467A1 (no)
CY (1) CY1109468T1 (no)
DE (1) DE602004022781D1 (no)
DK (1) DK1601694T3 (no)
ES (1) ES2330220T3 (no)
MX (1) MXPA05009717A (no)
NO (1) NO20054630L (no)
NZ (2) NZ541898A (no)
PL (1) PL1601694T3 (no)
PT (1) PT1601694E (no)
SI (1) SI1601694T1 (no)
TW (2) TWI439285B (no)
WO (1) WO2004081190A2 (no)
ZA (1) ZA200506879B (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
TWI439285B (zh) * 2003-03-10 2014-06-01 Merck Sharp & Dohme Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑
AU2004239288B2 (en) * 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
JP4903061B2 (ja) * 2004-02-17 2012-03-21 シェーリング コーポレイション Ｉｌ−２３活性を調節する方法；関連する試薬
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
RU2006135119A (ru) * 2004-03-05 2008-04-10 Аркемикс Корп. (Us) Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006068987A2 (en) * 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
WO2007005647A2 (en) * 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the il-12 family of cytokines
AU2012258409B2 (en) * 2005-06-30 2016-01-07 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
PT1896073E (pt) 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
ES2347690T3 (es) * 2005-08-25 2010-11-03 Eli Lilly And Company Anticuerpos anti-il-23.
ME02705B (me) * 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
EP2116258A1 (en) 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
PT2548577T (pt) * 2005-12-29 2017-05-29 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
EP1882699A1 (en) * 2006-07-27 2008-01-30 Heinfried Radeke Regulation of interleukin-23
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
US8119133B2 (en) 2007-02-28 2012-02-21 Schering Corporation Engineered anti-IL-23R antibodies
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
AU2008273814A1 (en) * 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite IL-23 receptor antagonists and uses thereof
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20100331545A1 (en) 2007-10-24 2010-12-30 Nippon Chemiphar Co., Ltd. Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
NZ588674A (en) * 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010027767A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
ES2469802T3 (es) * 2008-10-20 2014-06-20 Valipharma Métodos y usos que implican aberraciones genéticas de NAV 3 y expresión aberrante de múltiples genes
EP2414393A1 (en) * 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
SG175276A1 (en) * 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
EP2456787A4 (en) * 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
USRE49026E1 (en) 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
SG11201705728RA (en) 2015-02-04 2017-08-30 Boehringer Ingelheim Int Methods of treating inflammatory diseases
JP6871876B2 (ja) 2015-03-11 2021-05-19 ラッシュ ユニヴァーシティ メディカル センター がんを治療するための組成物と方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
US20230220031A1 (en) * 2020-04-17 2023-07-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered il-12 and il-23 polypeptides and uses thereof
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5856457A (en) 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
ES2300276T5 (es) * 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas
CA2408571C (en) * 2000-05-10 2014-04-29 Schering Corporation Mammalian receptor proteins; related reagents and methods
EP1326978A2 (en) * 2000-10-06 2003-07-16 Immunex CorporatioN Hematopoietin receptors hpr1 and hpr2
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
TWI439285B (zh) * 2003-03-10 2014-06-01 Merck Sharp & Dohme Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑

Also Published As

Publication number Publication date
TW200505479A (en) 2005-02-16
TWI439285B (zh) 2014-06-01
NO20054630D0 (no) 2005-10-07
NZ567860A (en) 2009-11-27
WO2004081190A3 (en) 2005-02-03
ES2330220T3 (es) 2009-12-07
DE602004022781D1 (de) 2009-10-08
JP2007197453A (ja) 2007-08-09
US20040223969A1 (en) 2004-11-11
EP2108658A1 (en) 2009-10-14
WO2004081190A2 (en) 2004-09-23
AU2010212372B2 (en) 2012-12-20
SI1601694T1 (sl) 2010-01-29
CY1109468T1 (el) 2014-08-13
MXPA05009717A (es) 2005-10-18
AU2004219625B2 (en) 2010-08-19
EP1601694A2 (en) 2005-12-07
US20080057058A1 (en) 2008-03-06
PL1601694T3 (pl) 2010-02-26
CN1759123B (zh) 2011-04-13
DK1601694T3 (da) 2009-12-14
HK1076477A1 (en) 2006-01-20
AU2004219625B9 (en) 2010-12-23
JP2014005286A (ja) 2014-01-16
JP2006520781A (ja) 2006-09-14
JP4605798B2 (ja) 2011-01-05
CL2004000467A1 (es) 2005-05-06
CA2518262A1 (en) 2004-09-23
CA2518262C (en) 2014-05-06
TW201141521A (en) 2011-12-01
US7282204B2 (en) 2007-10-16
US8034341B2 (en) 2011-10-11
PT1601694E (pt) 2009-12-03
EP1601694B1 (en) 2009-08-26
AU2010212372A1 (en) 2010-09-09
CN1759123A (zh) 2006-04-12
BRPI0408247A (pt) 2006-03-01
ATE440864T1 (de) 2009-09-15
AU2004219625A1 (en) 2004-09-23
US20120034219A1 (en) 2012-02-09
TWI357336B (en) 2012-02-01
EP2108658B1 (en) 2016-06-08
JP2011032275A (ja) 2011-02-17
US20100003251A1 (en) 2010-01-07
NZ541898A (en) 2008-07-31
ZA200506879B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
NO20054630L (no) Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser
ZA200606620B (en) Methods of modulating IL-23 activity ; related reagents
NO20053590D0 (no) Dobbel modusenhet for kortdistanse, hoyrate og langstanse, lavere dataratekommunikasjon.
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
NO20054735D0 (no) Autentisering mellom et CDMA- og et GSM-nett for globalt samband
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
DK1287140T3 (da) Antistofmolekyler, der har specificitet overfor human tumornekrosefaktor-alfa og anvendelse deraf
DE60331355D1 (de) Steuerung für multimedia-sitzungen
EA201301072A1 (ru) Антитела против il-23p19 и их применение
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
DE602005017753D1 (de) Mittel für die transdermale verabreichung von nikotin
TW200531679A (en) Methods of modulating cytokine activity; related reagents
DE602004008589D1 (de) Informationskommunikationssystem, sendevorrichtung, sendeverfahren und computerprogramm
IS7815A (is) 3-Fenýl setið pýridóindólón, framleiðsla og meðferðarleg notkun þess.
UY28344A1 (es) Nuevos compuestos
IS2704B (is) Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini
MXPA05012297A (es) Indazol que tiene actividad analgesica.
ITMI20021917A1 (it) Attivatore per la formazione di gel piastrinico, gel di plasma povero di piastrine o gel di plasma ricco di piastrine.
ATE312077T1 (de) Peptiddeformylase-hemmer
DK1646649T3 (da) Macc1-polypeptid og dets anvendelse til tumordiagnostik og tumorterapi.
ATE294167T1 (de) Chemische verbindungen
NL1021524A1 (nl) Menginrichting.
DE502005000976D1 (de) Tunnelgerät zum Aushärten von Nagelgel sowie UV-Lampe
ATE309984T1 (de) Peptid-deformylase-hemmer

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application